Company: XOMAP
Filing Date: 2025-11-21
Form Type: 8-K
Source: 0001193125-25-290638
Chunk: 0

Company: XOMA Royalty Corp
Filing Date: 2025-11-21
Form: 8-K
Item: Item 2.01
Chunk 0
---
Item 2.01      Completion of Acquisition or Disposition of Assets.  

As previously disclosed, XOMA Royalty Corporation (“ XOMA”) entered into a share purchase agreement, dated August 3, 2025 (as amended to date, the “ Purchase Agreement”), with LAVA Therapeutics N. V., a public limited liability company ( naamloze vennootschap) organized under the laws of The Netherlands (the “ LAVA”). In accordance with the Purchase Agreement, on August 15, 2025, XOMA commenced a tender offer (the “ Offer”) to purchase all of LAVA’s issued and outstanding common shares, with a nominal value of €0.12 per share (“ Shares”) for a price per Share of (i) $1.04 (the “ Cash Amount”), payable subject to any applicable tax withholding and without interest, and (ii) one non-transferablecontractual contingent value right (“ CVR”) for each Share, which shall represent the right to receive potential payments, in cash, described in, and subject to and in accordance with the terms and conditions of, the CVR Agreement (as described below). Capitalized terms used and not otherwise defined in this Form8-Kshall have the meanings assigned to such terms in the Offer to Purchase (as defined below).